Novavax (NASDAQ:NVAX) Receives “Buy” Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Novavax (NASDAQ:NVAX) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $19.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on NVAX. Cantor Fitzgerald initiated coverage on shares of Novavax in a report on Friday, October 24th. They set an “overweight” rating and a $18.00 price objective on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a report on Monday, December 29th. TD Cowen dropped their price target on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. HC Wainwright lifted their price target on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, B. Riley reissued a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Novavax in a report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.25.

Novavax Stock Performance

Shares of Novavax stock opened at $8.20 on Tuesday. The business has a 50-day simple moving average of $7.01 and a 200 day simple moving average of $7.67. Novavax has a one year low of $5.01 and a one year high of $10.64. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.27 and a quick ratio of 2.24. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 4.58 and a beta of 2.37.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. Novavax had a negative return on equity of 217.02% and a net margin of 32.10%.The firm’s revenue was down 16.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.76) EPS. On average, research analysts anticipate that Novavax will post -1.46 earnings per share for the current fiscal year.

Institutional Trading of Novavax

Hedge funds have recently bought and sold shares of the business. Shah Capital Management grew its stake in Novavax by 23.3% in the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock valued at $97,835,000 after purchasing an additional 2,747,000 shares during the period. Bank of America Corp DE grew its position in Novavax by 0.5% during the third quarter. Bank of America Corp DE now owns 3,101,074 shares of the biopharmaceutical company’s stock valued at $26,886,000 after buying an additional 15,685 shares during the period. Allianz Asset Management GmbH increased its holdings in Novavax by 162.6% during the third quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock worth $12,222,000 after buying an additional 872,987 shares during the last quarter. TSP Capital Management Group LLC raised its position in Novavax by 3.5% in the second quarter. TSP Capital Management Group LLC now owns 1,399,065 shares of the biopharmaceutical company’s stock worth $8,814,000 after acquiring an additional 46,900 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Novavax by 6.3% during the 4th quarter. SG Americas Securities LLC now owns 976,388 shares of the biopharmaceutical company’s stock worth $6,561,000 after purchasing an additional 57,705 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax signed a non‑exclusive license with Pfizer allowing Pfizer to use Matrix‑M for up to two disease areas; Novavax will receive a $30M upfront payment, is eligible for up to $500M in development/sales milestones, plus high mid‑single digit royalties — a clear near‑term cash and revenue catalyst. Novavax Announces Entering into a License Agreement with Pfizer
• Positive Sentiment: Deal coverage across outlets highlights the commercial validation of Matrix‑M and has driven intraday buying interest. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Some analysts reiterated bullish views after the partnership: H.C. Wainwright reaffirmed a Buy rating, citing expanding Matrix‑M licensing as upside potential. Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating
• Neutral Sentiment: Market commentary and trade reports (Benzinga, Schaeffers, MSN) are amplifying the deal and the stock’s intraday move; useful for momentum but not new fundamentals beyond the announced terms. Novavax Stock Pops After Pfizer Licensing Agreement
• Negative Sentiment: Bank of America reiterated a Sell and raised its $7 price target, warning that execution risks, long‑dated cash flows and weak COVID demand undermine Novavax’s profitability outlook — a reminder of the company’s operational and market risks despite the licensing revenue. Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook
• Negative Sentiment: Wide analyst divergence (examples: BTIG’s $19 target vs. BofA’s $7) highlights valuation uncertainty — short‑term upside from licensing cash is real, but longer‑term earnings depend on execution, market demand for vaccines, and successful monetization of Matrix‑M across partners. Benzinga

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.